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Abstract 
Perfluoroalkyl substances (PFAS) are highly persistent chemicals that might be associated with 
asthma and allergy, but the associations remain unclear. Therefore, this study examined whether 
pre- and post-natal PFAS exposure was associated with childhood asthma and allergy. Measles, 
mumps and rubella (MMR) vaccination in early life may have a protective effect against asthma 
and allergy and is therefore taken into account when evaluating these associations. In a cohort of 
Faroese children whose mothers were recruited during pregnancy, serum concentrations of five 
PFAS were measured: Perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid 
(PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorodecanoic 
acid (PFDA) at three timepoints (maternal serum in pregnancy week 34-36 and child serum at 
ages 5 and 13 years) and determined their association with immunoglobulin E (IgE) (cord blood 
and at age 7 years) and asthma/allergic diseases (questionnaires at ages 5 and 13 years and skin 
prick test at age 13 years). A total of 559 children were included in the analyses. Interactions 
with MMR vaccination were evaluated. Among 22 MMR-unvaccinated children, higher levels of 
the five PFAS at age 5 years were associated with increased odds of asthma at ages 5 and 13. 
The associations were reversed among MMR-vaccinated children. Pre-natal PFAS exposure was 
not associated with childhood asthma or allergic diseases regardless of MMR vaccination status. 
In conclusion, PFAS exposure at age 5 was associated with increased risk of asthma among a 
small subgroup of MMR-unvaccinated children but not among MMR-vaccinated children. While 
PFAS exposure may impact immune system functions, this study suggests that MMR 
vaccination might be a potential effect-modifier. 
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Introduction 
Perfluoroalkyl substances (PFAS) constitute a group of highly persistent chemicals used 
in a variety of products including furniture, carpets, clothing, food packaging, and firefighting 
foams (Fromme et al. 2009). PFAS are found in human serum worldwide (Houde et al. 2006), 
and children appear to have a greater exposure than teenagers and adults (Trudel et al. 2008; 
Kato et al. 2009). Recently, higher serum-PFAS concentrations in childhood have been associ-
ated with increased odds of concurrent asthma (Dong et al. 2013), perhaps due to a shift towards 
a T-helper type 2 cell (TH2) immune response (Dong et al. 2011) as seen in allergic asthma and 
allergic diseases. However, other studies could not replicate this association (Humblet et al. 
2014; Stein et al. 2016). Reported associations between pre-natal PFAS exposure and asthma, 
wheezing, and other allergic diseases in children also have not been consistent (Wang et al. 
2011; Okada et al. 2012, 2014; Granum et al. 2013; Smit et al. 2015).  
Furthermore, Measles, mumps and rubella (MMR) vaccination in early life may have a 
protective effect against asthma or asthma symptoms (Gruber et al. 2003; Roost et al. 2004), an 
association that was previously substantiated in our analyses (Timmermann et al. 2015). The 
protective effect is possibly due to the elicitation of a TH1-biased response (Pabst et al. 1997; 
Ovsyannikova et al. 2003), and it is possible that a TH1-biased response induced by MMR 
vaccination could suppress a PFAS induced TH2 immune response thus minimizing the effect of 
PFAS on asthma among MMR-vaccinated children. 
The objective of the present study was therefore to investigate whether pre- or postnatal PFAS 
exposure was associated with asthma and allergic diseases in a birth cohort while considering the 
potential effectmodification by MMR-vaccination. 
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Materials and Methods 
Sample population 
Data were collected as part of the Children’s Health and Environment in the Faroe 
Islands (CHEF) study (Grandjean et al. 2010; Heilmann et al. 2010; Timmermann et al. 2015). 
The birth cohort was formed in 1997-2000, and a blood sample for measuring environmental 
exposures was obtained when the women were included in gestational week 34-36. Obstetric 
information was recorded, and a cord blood sample was obtained at birth. At ages 5, 7, and 13 
years, children were invited for physical examinations (including blood sampling) and parents 
filled out a questionnaire together with a research nurse. 
MMR vaccinations were routinely administered at 15 mo-of-age; vaccination dates were 
obtained from the child’s vaccination card at age 5. There were no specific contraindications. 
Children were considered eligible for this study if they attended the age-5 examination. They 
were excluded if they had had measles or if no information was provided about this disease 
(Timmermann et al. 2015). 
Written informed consent was obtained from the parents of all children included in the 
study. The study was carried out in accordance with the Helsinki Declaration and was approved 
by the ethical review committee serving the Faroe Islands and the U.S. (Harvard) institutional 
review board (IRB). 
Asthma and allergy outcomes 
Total Immunoglobulin E (IgE) and A (IgA) concentrations were quantified in cord blood 
by ImmuniCAP and in-house ELISA. Analyses have been described in more detail elsewhere 
(Timmermann et al. 2015).  IgE measures from samples with IgA concentrations > 50 µg/ml 
were disregarded due to possible contamination with maternal blood (Bonnelykke et al. 2010). 
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At age 5, parents were asked whether the child had been diagnosed with or was suspected to 
suffer from asthma and whether the child had been diagnosed with hypersensitivity or allergy. At 
age 7, a blood sample was drawn from which total IgE was quantified. At age 13, parents were 
asked whether the child had ever suffered from asthma. Rhinoconjunctivitis symptoms (in past 
12 months) and eczema (ever) were also identified through the parental questionnaire using 
questions from the International Study of Asthma and Allergies in Childhood (ISAAC) as 
previously described (Timmermann et al. 2015). The children underwent a skin prick test (SPT) 
with extracts (Soluprick, ALK, Hørsholm, Denmark) of five common allergens (birch/grass 
pollen, dog/cat dander, and house dust mite [Dermatophagoides pteronyssinus]) at age 13. A 
wheal size ≥ 3 mm in diameter resulting from any of the five allergens was considered positive.  
PFAS analysis 
Perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluoro-
octanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) 
were measured in maternal pregnancy serum and child serum at ages 5 and 13 (Grandjean et al. 
2012). Analyses were carried out by isotope dilution and online solid-phase extraction followed 
by high performance liquid chromatography with triple quadropole mass-spectrometric analysis 
according to the methods of Haug et al. (2009). PFOS was quantified by integration of two 
adjacent peaks, which represent the branched isomers and the linear isomer. The between batch-
imprecision was < 7.7% and the limit of detection (LOD) for the five PFAS was 0.03 ng/ml. All 
five PFAS were found at concentrations above the LOD in all maternal and child serum samples. 
Potential confounders 
Information about variables known to be associated with asthma and/or allergic diseases 
(Bodner et al. 1998; Reichman and Nepomnyaschy 2008; Just et al. 2010; Nagel et al. 2010; 
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Civelek et al. 2011; Herr et al. 2012; Chang et al. 2013; de Vries et al. 2014; Dogaru et al. 2014; 
Mu et al. 2014; Netting et al. 2014) was obtained from the recruiting midwife’s chart (maternal 
pre-pregnancy BMI (weight/hight2), maternal smoking during pregnancy (none/any), premature 
birth (< 37 weeks / ≥ 37 weeks), birth season (spring: March-May; summer: June-August; fall: 
September-November; winter: December-February), sex, birth weight and parity (zero/one/more 
than one previous birth), the parental questionnaires at age 5 (total duration of breastfeeding = 
exclusive and partial breastfeeding in months, number of siblings, parental smoking at home 
[yes/no], weekly fish dinners, and daycare attendance [yes/no]) and age 13 (fish dinners, 
domestic pets, and family history of asthma and allergic diseases [no/from one parent’s side/from 
both parents’ sides]). 
Statistics 
Among children included in this study, all missing values were imputed using multiple 
imputation by chained equations with 40 imputations based on all exposures, outcomes, and 
potential confounders, as well as three auxiliary variables (Azur et al. 2011), i.e., information 
about the father’s primary education (7th-8th Grade/9th-10th Grade), whether the child had lived 
abroad between ages 7 and 13 (yes/no), and whether the child is allergic to anything (yes/no or 
do not know). IgE and PFAS concentrations were right skewed and therefore were log10–trans-
formed to avoid violating model assumptions when performing imputations and conducting 
association analyses. 
Each interaction between MMR vaccination and PFAS concentration measures were 
tested in relation to all asthma and allergic disease measures (except cord blood IgE, which could 
not have been affected by subsequent MMR vaccination) in marginal analyses using the unim-
puted data. Interactions considered to be consistent (interactions with p < 0.2 in the same 
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direction for at least three out of five PFAS measures) were included in the imputation of the 
asthma and allergic disease measures on which they were found to interact. 
All imputations were performed using the mi impute chained command in Stata version 
14.0 (StataCorp, College Station, TX). The imputation models are described in further detail in 
Appendix A. Using the imputed data, associations between serum concentrations of each PFAS 
and asthma and allergic diseases at ages 5 and 13 were determined in logistic regression models, 
and associations between each PFAS and total IgE in cord blood and at age 7 were determined in 
linear regression models. If interactions were identified in the marginal analyses using the 
unimputed data, an interaction term for PFAS exposure and MMR vaccination was included in 
the model, and potential confounders were included if associated with the PFAS measures 
(Appendix B). When investigating interactions, information about birth weight and family 
history of chronic bronchitis/asthma was also included in the models because these factors are 
associated with MMR vaccination uptake in the Faroese cohort and so might confound the asso-
ciation between MMR vaccination and asthma/allergic diseases (Timmermann et al. 2015). Since 
both PFAS concentrations and IgE measures were log-transformed, the estimates of association 
were converted to express the percent change in IgE associated with a doubled serum-PFAS 
concentration in the linear regression models and the odds ratio with a doubling of the PFAS 
exposure in the logistic regression models. 
Sensitivity analyses were also performed in which analyses were conducted using the unimputed 
data and information about maternal education (none/any education above primary school), 
maternal pregnancy serum dichlorodiphenyldichloroethylene (DDE), and the sum of maternal 
pregnancy serum polychlorinated biphenyl (PCB) concentrations were included one at a time. A 
simplified sumPCB concentration was calculated as the sum of congeners CB-138, CB-153, and 
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CB-180 multiplied by 2. Lastly, subgroup analyses for atopic and non-atopic asthma was 
performed and separately compared each group to children with no asthma. At age 5, atopic 
asthma was classified as having both asthma and allergy (41% of asthma cases), and at age 13, 
atopic asthma was classified as having both asthma and positive SPT (59% of asthma cases). In 
these analyses only children with complete information about both asthma and allergy/SPT were 
included. All analyses were performed in Stata version 14.0. 
Results 
Informed consent was obtained from 648 mothers of whom eight had twins, thus leaving 
640 singleton children. Among these, 59 children were not seen at age 5 and 22 were excluded 
due to having a history of measles infection (n = 7) or not having provided information about 
measles infection (n = 15) (Timmermann et al. 2015), leaving 559 children (87%) eligible for the 
study (Figure 1). The 81 (59 + 22) ineligible children had mothers with lower parity. Further 
more, among the ineligible children, mothers of 76 children had provided a blood sample in 
which PFAS was measured. These 76 mothers had lower serum concentrations of PFDA and 
PFNA, and higher levels of PFOA. Finally, 31 of the ineligible children attended the 13-year 
examination. These 31 children more often had asthma at age 13 compared to the 491 (522-31) 
children who attended the 13-year examination and were eligible for the study. No other signi-
ficant (p < 0.05) differences between the eligible and ineligible children were found with regard 
to outcomes, exposures, or potential confounders. 
The distributions of exposures, outcomes, and potential confounders are shown in Table 
1. Among the 559 mothers included in this study, 30 did not provide a blood sample for PFAS 
analysis during pregnancy. Furthermore, 35 children did not provide a blood sample for PFAS 
analysis at age 5, and 68 children did not participate in the examination at age 13. An additional 
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six children did not provide a blood sample for PFAS analysis at age 13. These missing values 
were imputed along with missing information about the outcomes and covariates. In the 
unimputed data the median PFHxS and PFOS concentrations were highest (4.5 and 27.4 ng/ml) 
in maternal pregnancy serum and lowest in child serum at age 13, while the medians for PFOA 
and PFNA were highest in age-5 child serum (4.0 and 1.0 ng/ml); PFDA concentrations were 
stable across the three timepoints (0.3 ng/ml). At age 5, 14.2% and 13.5% were reported to have 
asthma and allergy respectively; at age 13, 16.9% had had asthma, 38.7% had a positive SPT, 
12.0% had allergic rhinoconjuctivitis, and 20.8% had had eczema. Only 22 out of 555 children 
had not received the MMR vaccination scheduled for age 15 months before the 5-year examina-
tion (Table 1). PFAS distributions including minimum and maximum values for children with 
and without asthma at ages 5 and 13 years by MMR vaccination status are shown in Appendix C. 
None of the small subgroups contain extreme values. As previously shown, children without 
MMR-vaccination had higher risk of asthma and allergic diseases (Timmermann et al. 2015). 
In the marginal analyses on the unimputed data, no MMR vaccination interaction with 
maternal PFAS concentrations was found in relation to any of the outcome measures, but inter-
actions between MMR vaccination and age-5 or age-13 PFAS in relation to some of the asthma 
and allergic disease measures were observed. Thus, increased serum-PFAS concentrations at age 
5 tended to be associated with higher odds of a history of asthma at ages 5 and 13 and allergy at 
age 5 among the MMR-unvaccinated children, and among MMR-vaccinated children, an 
increase in serum-PFAS concentrations at age 5 tended to be associated with reduced odds of 
history of asthma at ages 5 and 13 and allergy at age 5. Few of these associations were, however, 
significant; the interaction between MMR vaccination and PFASs at age 5 was significant for 
PFOA in relation to asthma at ages 5 and 13 and for PFNA and PFDA in relation to asthma at 
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age 5. The same pattern was found in the association between PFAS concentrations at age 13 and 
atopic eczema at age 13 (data not shown). 
When using the data with imputations and taking potential confounding factors into 
account, the pattern described above persisted. As shown in Table 2, a doubling of the serum-
PFOA concentration at age 5 was significantly associated with 10-fold increased odds of asthma 
at ages 5 and 13 among the MMR-unvaccinated children. A doubling of the age 5 serum-PFNA 
concentration was likewise significantly associated with similarly increased odds of asthma at 
both ages among the MMR-unvaccinated children, and a doubling of the age 5 serum-PFDA 
concentration showed a significant, though slightly weaker, association with asthma at age 5 
among the MMR-unvaccinated children (Table 2). The interaction between MMR vaccination 
and age-5 PFAS was significant for PFOA, PFNA and PFDA in relation to asthma at ages 5 and 
13 and for PFHxS in relation to asthma at age 5 (Table 2). Results were similar when maternal 
education, pregnancy serum-DDE, or pregnancy serum-PCB concentrations were included in an 
analysis using the unimputed data (results not shown). 
In the adjusted analyses, in which interactions with MMR vaccination were not included 
(because no interaction was found in the marginal analyses), no clear patterns of association 
were found. Specifically, no associations were found between PFAS exposure at age 5 and total 
IgE at age 7, positive SPT at age 13, allergic rhinoconjunctivitis at age 13 or atopic eczema at 
age 13 (Table 2). Increased maternal serum-PFHxS concentrations were associated with 
increased odds of atopic eczema at age 13 (Table 3), but given the large number of analyses 
conducted, the risk of Type I errors is increased, and this one significant association is likely to 
be a chance finding. No associations were found between maternal PFAS exposure and the other 
outcome measures (Table 3). Additionally, increased serum-PFHxS and serum-PFNA 
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concentrations at age 13 were associated with reduced odds of asthma and allergic 
rhinoconjunctivitis, respsectively (Table 4). However, since no other significant associations 
were found with PFAS exposure at age 13, these associations could also be chance findings. 
When dividing asthma into atopic and non-atopic asthma, the interactions between MMR 
vaccination and PFAS at age 5 persisted for atopic asthma, whereas no significant interactions or 
associations were seen for non-atopic asthma (Table 5). Among MMR-unvaccinated children, a 
doubling in the concentration of the PFAS at age 5 was significantly associated with 9-75-fold 
higher odds of atopic asthma, and a doubling of the PFNA concentration was likewise signifi-
cantly associated with 7-fold higher odds of atopic asthma at age 13 (Table 5). 
Discussion 
Serum-PFAS concentrations at age 5 were associated with increased odds of asthma 
history at ages 5 and 13 in children who had not been MMR-vaccinated, although the numbers 
were small. The associations were reversed among MMR-vaccinated children. The same 
tendencies, though not significant, were seen in the association between serum-PFAS at age 5 
and history of allergy at age 5 and between serum-PFAS at age 13 and history of atopic eczema 
at age 13. 
A Taiwanese case-control study reported that increased PFAS exposures were associated 
with concurrent asthma among 10-15-year-olds (Dong et al. 2013), while a cross-sectional study 
using the U.S. National Health and Nutrition Examination Survey (NHANES) data (1999-2000, 
2003-2004, 2005-2006, 2007-2008) of 12-19 year-olds found that serum-PFOA was associated 
with increased odds of asthma while PFOS showed a negative association (Humblet et al. 2014), 
and finally a recent study using NHANES data (2005-2006) of 12-19 year-olds did not find any 
association between PFAS and asthma but found that higher serum-PFOS concentrations were 
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associated with reduced odds of sensitization to any allergen, while increased PFOA and PFNA 
were associated with increased serum IgE (Stein et al. 2016). Neither of these studies examined 
MMR vaccinations or other factors that might contribute to the different findings. 
In regard to pre-natal PFAS exposure, cord blood PFOS and PFOA concentrations have 
been found to correlate positively with cord blood IgE levels in boys (Wang et al. 2011), while 
high maternal PFOA concentrations were associated with decreased cord blood IgE levels in 
girls (Okada et al. 2012) and reduced risk of allergic diseases during the first 24 months (Okada 
et al. 2014). Recent studies found that maternal PFOA concentrations were inversely associated 
with current wheezing among Ukrainian but not in Greenlandic children aged 5-9 years (Smit et 
al. 2015) and other types of maternal PFAS were inversely associated with allergic diseases 
among 4-year-old children (Goudarzi et al. 2016). Several other analyses, however, showed no 
associations between pre-natal exposure to PFAS and cord blood IgE (Ashley-Martin et al. 2015) 
or asthma and allergy in childhood (Wang et al. 2011; Okada et al. 2012; Granum et al. 2013), 
which is in accordance with the current findings. 
The mechanisms underlying immunomodulating effects of various PFAS are far from 
fully understood, but these chemicals have been shown to affect activation of human immune 
cells and reduce both pro- and anti-inflammatory cytokine production in vitro (Corsini et al. 
2014). In mice, PFOS exposure has been shown to lead to an increase in interleukin (IL)-4 and 
IL-10 and to decrease IL-2 and interferon (IFN)-g, thereby indicating a shift towards a TH2 
immune response (Dong et al. 2011). If such a shift occurs, it could perhaps explain the positive 
association between serum-PFAS concentrations and asthma among the MMR-unvaccinated 
children in the current analyses, while the MMR vaccination may rather shift the immune 
response towards a more TH1-prone state (Pabst et al. 1997; Ovsyannikova et al. 2003), thereby 
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preventing or counteracting a PFAS-induced TH2-shift. If PFAS exposure affects the TH1/TH2 
balance, an interaction between MMR vaccination and serum-PFAS concentrations thus seems 
plausible. 
If MMR vaccination modifies the effect of PFAS on asthma as suggested by the current 
findings, differences in vaccination schedules might explain why the association between PFAS 
exposure and asthma differs between studies from different parts of the world. However, the 
range of serum-PFAS concentrations is also important. Both the age 5 and 13-year serum-PFAS 
concentrations of children in this study were lower than among Taiwanese children, except for 
PFOA, which was higher (Dong et al. 2013), and the age 5 serum-PFAS concentrations were 
similar to those of American children whereas the age 13 serum-PFAS concentrations were 
lower in the present study (Humblet et al. 2014). It is possible MMR vaccination can protect 
against adverse effects of PFAS on asthma only when PFAS concentrations are relatively low. 
It is important to note that a main limitation of this study is that very few cohort children 
were not MMR-vaccinated, which limited the power to detect interactions between MMR 
vaccination and PFAS concentrations. Therefore, the present hypothesis about MMR vaccination 
modifying the association between PFAS and asthma needs to be re-examined in populations 
with a larger number of MMR-unvaccinated children. In addition, this study conducted a large 
number of analyses, which increased the risk of chance findings. Therefore, it did not look for 
single significant associations but rather patterns in the associations. 
As common in cohort studies, follow-up was not complete, and this study compensated 
for missing data by multiple imputations. Assuming that data were missing at random, this 
approach would be expected to produce more correct estimates of the true associations (Azur et 
al. 2011). However, those cohort members who did not provide information on history of 
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measles infection had to be excluded. They differed from those included with regard to maternal 
serum-PFAS concentrations and asthma at age 13, and one cannot rule out the possibility of 
some selection bias. However, with 87% of the original cohort included in the present study, it is 
believed that any potential bias was minimal. These analyses showed that some confounding did 
occur, but only marginally affected the results. However, in observational studies, the possibility 
of residual confounding can never be excluded. 
Imprecision of the asthma measures must also be considered. At age 13, questionnaire 
data about asthma have been shown to have a high sensitivity and specificity in relation to 
clinical asthma (Fuso et al. 2000), but this measure is probably less precise at age 5 due to 
difficulties in distinguishing asthma from bronchitis. Any misclassification is, however, unlikely 
to be associated with the PFAS exposure or misclassification of PFAS exposure; therefore any 
bias likely would have been towards null (Kristensen 1992). 
Overall, pre-natal PFAS exposure did not seem to affect the risk of childhood asthma or 
allergy. Much previous research has focused on pre-natal exposure, but both the pre- and post-
natal periods are known to be important in establishing an immune deviation from TH2 to TH1 
skewed immunity (Romagnani 2014), and in this study, associations were found only with post-
natal exposure. In addition, it has been established that children are highly exposed to PFAS in 
early life through breastfeeding (Mogensen et al. 2015), emphasizing the need to further study 
the effects of post-natal PFAS exposure. 
Among the MMR-unvaccinated children, stronger associations were found between 
PFAS concentrations and asthma than between PFAS and other allergic diseases, and stronger 
associations were observed for atopic than for non-atopic asthma. This indicated that PFAS 
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exposure may affect development of allergy development. However, given the small number of 
unvaccinated children, these findings should be interpreted with caution. 
Conclusions 
Serum PFAS concentrations at age 5 years were associated with increased odds of asthma 
at ages 5 and 13 years among MMR-unvaccinated children. The associations were reversed 
among MMR-vaccinated children. Similar analyses failed to identify any association with pre-
natal PFAS exposure. These findings suggest that MMR vaccination should be considered as a 
potential effect-modifier in studies of adverse effects of PFAS on immune functions, but larger 
studies are needed to support the current findings. 
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Figure legend 
Figure 1. Flowchart of the experiment. 
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Table 1: Distribution of exposures, outcomes and potential confounders (pre-imputation) 
 
N = 559  Information collected  prenatally / at birth  
Information collected  
at age 5 / 7  
Information collected  
at age 13 
Continuous variables  Median  (25th-75th percentile) 
n  
missing  
Median  
(25th-75th percentile) 
n  
missing  
Median  
(25th-75th percentile) 
n  
missing 
PFHxS (ng/mL)  4.5 (2.2; 8.3) 30  0.6 (0.4; 0.9) 35  0.4 (0.3; 0.5) 74 
PFOS (ng/mL)  27.4 (23.3; 33.3) 30  16.8 (13.5; 21.1) 35  6.7 (5.2; 8.5) 74 
PFOA (ng/mL)  3.3 (2.5; 4.0) 30  4.0 (3.3; 5.0) 35  2.0 (1.6; 2.5) 74 
PFNA (ng/mL)  0.6 (0.5; 0.8) 30  1.0 (0.8; 1.2) 35  0.7 (0.6; 0.9) 74 
PFDA (ng/mL)  0.3 (0.2; 0.4) 30  0.3 (0.2; 0.4) 35  0.3 (0.2; 0.4) 74 
Total IgE (kU/L)  0.1 (0.0; 0.2) 62  21.8 (9.8; 70) 132  -  
Birth weight (kg)  3.8 (3.4; 4) 0  -   -  
Total months of breastfeeding  -   9 (6; 12) 3  -  
Maternal pre-pregnancy BMI (kg/m2)   23.1 (21.3; 25.7) 0  -   -  
Categorical variables  % (n/N) n  missing  % (n/N) 
n  
missing  % (n/N) 
n  
missing 
Asthma (questionnaire)  -   14.2 (78/550) 9  16.9 (83/491) 68 
Allergy (questionnaire)  -   13.5 (74/548) 11  -  
Positive skin prick test  -   -   38.7 (190/491) 68 
Allergic Rhinoconjunctivitis (questionnaire)  -   -   12.0 (59/491) 68 
Atopic eczema (questionnaire)      -   20.8 (102/491) 68 
Sex (girls)  47.2 (265/559) 0  -   -  
Premature birth (<=36 weeks)  1.2 (11/559) 0  -   -  
Birth season 
Summer  27.2 (152/559)        
Fall  24.0 (134/559) 0  -   -  
Winter  27.6 (154(559)        
Maternal parity 1  33.1 (185/559) 0  -   -  >=2  41.3 (231/559)     
Number of siblings  
1     35.3 (197/558)     
2  -   38.9 (217/558) 1  -  
>=3     19.2 (107/558)     
Received 15-months MMR vaccination  -   96.0 (533/555) 4  -  
Maternal smoking  29.7 (166/559) 0  -   -  
Parental smoking in the home     26.3 (146/556) 3  10 (49/490) 69 
Weekly fish dinners >1 – 2  36.1 (97/269) 290 a  40.9 (228/557) 2  43.4 (213/491) 68 >2  37.2 (100/269)  42.2 (235/557)  15.9 (78/491) 
Use of daycare  -   92.4 (510/552) 7    
Has furry pets  -      54.4 (266/489) 70 
Family history of chronic From one parent        33.2 (163/491)  
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bronchitis or asthma From both parents  -   -   4.7 (23/491) 68 
Do not know         5.3 (26/491) b  
Family history of eczema 
in children, allergic 
eczema and hay fever 
From one parent        44.0 (216/491)  
From both parents  -   -   11.2 (55/491) 68 
Do not know         6.5 (32/491) b  
Family history of allergy 
From one parent        32.9 (161/490)  
From both parents  -   -   7.8 (38/490) 69 
Do not know         11.4 (56/490) b  
Only 104 children had complete information i.e. no missing values on outcomes, exposures, or covariates. Compared to children with missing information on one or more 
of the variables, these 104 children had mothers with lower concentrations of PFHxS (median 2.1 vs. 5.7 ng/mL) and higher concentrations of PFNA (median 0.7 vs. 0.6 
ng/mL) tested using Wilcoxon rank-sum test. The 104 children also had lower concentrations of PFOS at age 5 (median 15.2 vs. 17.3 ng/mL) tested using Wilcoxon rank-
sum test, and they were more often born during the summer (36 % vs. 25 %) tested using Chi square test. No other significant (p<0.05) differences were found.  
a Information about maternal diet was not collected from the beginning of the study.  
b “Do not know”-answers were imputed along with the missing values. 
- Information was not obtained / not included in this study. 
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Table 2: Differences in IgE (%) and OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of serum-
PFAS concentrations at age 5 
N= 559  Age 5   Age 7  
Age 5 
PFASs 
MMR 
vaccination 
before age 5 
 Asthma a   Allergy a   IgE  
 OR (95% CI) p 
i  OR (95% CI) p 
i  % difference  (95% CI)  
PFHxS   no  3.57 (0.95; 13.43) 0.03  1.25 (0.41; 3.88) 0.56  -2.88 (-20.47; 18.61)  yes  0.81 (0.58; 1.14)  0.89 (0.63; 1.25)   
PFOS no  3.96 (0.55; 28.39) 0.18  6.15 (0.77; 49.23) 0.06  -9.38 (-37.17; 30.71)  yes  0.98 (0.55; 1.76)  0.80 (0.43; 1.49)   
PFOA no  10.37 (1.06; 101.93) 0.03  1.73 (0.32; 9.22) 0.21  7.87 (-25.22; 55.61)  yes  0.76 (0.41; 1.39)  0.55 (0.29; 1.06)   
PFNA no  12.52 (1.29; 121.67) 0.02  2.40 (0.57; 10.03) 0.11  -5.02 (-27.83; 25.00)  yes  0.72 (0.44; 1.18)  0.71 (0.43; 1.17)   
PFDA no  4.04 (1.05; 15.50) 0.02  2.21 (0.69; 7.06) 0.10  -7.59 (-26.58; 16.29)  yes  0.71 (0.48; 1.06)  0.79 (0.52; 1.19)   
   Age 13 
Age 5 
PFASs 
  
Asthma a 
 
 Positive skin prick test  
Allergic 
rhinoconjunctivitis 
(past 12 months) 
 Atopic eczema 
  OR (95% CI) p i  OR (95% CI)  OR (95% CI)  OR (95% CI) 
PFHxS   no  2.51 (0.77; 8.16) 0.10  0.95 (0.75; 1.20)  0.80 (0.57; 1.14)  0.92 (0.70; 1.22) yes  0.90 (0.63; 1.27)  
PFOS no  5.41 (0.62; 47.16) 0.12  0.76 (0.49; 1.18)  0.63 (0.33; 1.20)  0.80 (0.46; 1.39) yes  0.94 (0.51; 1.74)  
PFOA no  9.92 (1.06; 93.22) 0.02  1.15 (0.75; 1.77)  1.01 (0.54; 1.89)  0.72 (0.42; 1.25) yes  0.65 (0.35; 1.20)  
PFNA  no  6.85 (1.05; 44.69) 0.02  0.79 (0.57; 1.10)  0.63 (0.37; 1.07)  0.79 (0.51; 1.23) yes  0.71 (0.44; 1.16)  
PFDA  no  2.87 (0.84; 9.79) 0.03  0.79 (0.59; 1.05)  0.71 (0.47; 1.08)  0.92 (0.64; 1.31) yes  0.71 (0.48; 1.06)  
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, 
allergic eczema and hay fever, maternal pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of 
breastfeeding, fish intake at age 5, number of siblings, and daycare attendance at age 5. 
a Additionally adjusted for birth weight, and family history of chronic bronchitis/asthma. 
i p-value for PFAS/MMR vaccination interaction. 
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Table 3: Differences in IgE (%) and OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of maternal 
serum-PFAS concentrations 
N= 559  Cord blood  Age 5  Age 7 
Maternal 
PFASs 
 IgE  Asthma  Allergy  IgE 
 % difference  (95% CI) 
 OR (95% CI)  OR (95% CI)  % difference  (95% CI) 
PFHxS    -0.17 (-9.33; 9.93)  0.99 (0.80; 1.22)  1.20 (0.95; 1.53)  6.35 (-6.89; 21.48) 
PFOS   -6.28 (-30.29; 25.99)  1.21 (0.64; 2.29)  0.73 (0.38; 1.41)  18.61 (-24.06; 85.24) 
PFOA   2.81 (-19.29; 30.93)  1.37 (0.81; 2.32)  0.92 (0.53; 1.57)  -5.15 (-31.92; 32.14) 
PFNA   0.94 (-17.67; 23.75)  1.03 (0.67; 1.59)  0.82 (0.52; 1.31)  21.11 (-11.70; 66.12) 
PFDA   3.23 (-14.29; 24.35)  1.09 (0.72; 1.65)  0.83 (0.54; 1.27)  24.73 (-5.68; 64.94) 
  Age 13 
Maternal 
PFASs 
 
Asthma  Positive skin prick test  
Allergic 
rhinoconjunctivitis 
(past 12 months) 
 Atopic eczema 
 OR (95% CI)  OR (95% CI)  OR (95% CI)  OR (95% CI) 
PFHxS    0.98 (0.79; 1.20)  0.94 (0.79; 1.12)  1.14 (0.88; 1.46)  1.32 (1.08; 1.62) 
PFOS   1.61 (0.84; 3.08)  1.25 (0.75; 2.11)  1.05 (0.51; 2.17)  0.75 (0.42; 1.34) 
PFOA  1.12 (0.67; 1.88)  1.16 (0.76; 1.77)  1.18 (0.65; 2.15)  1.36 (0.85; 2.19) 
PFNA   1.21 (0.77; 1.88)  0.97 (0.69; 1.38)  0.86 (0.52; 1.41)  0.81 (0.55; 1.20) 
PFDA   1.26 (0.83; 1.92)  1.02 (0.74; 1.41)  0.88 (0.56; 1.38)  0.92 (0.64; 1.32) 
Missing values were imputed using multiple imputation. All analyses were adjusted for maternal parity, family history of 
eczema in children, allergic eczema and hay fever, maternal pre-pregnancy BMI, maternal smoking during pregnancy, 
maternal fish intake during pregnancy, and duration of breastfeeding. 
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Table 4: OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of serum-PFAS concentrations at age 
13 
N= 559  Age 13 
Age 13 
PFASs 
MMR 
vaccination 
before age 5 
 
Atopic eczema a 
 
Asthma  Positive skin prick test  
Allergic 
rhinoconjunctivitis 
(past 12 months) 
 OR (95% CI) p i  OR (95% CI)  OR (95% CI)  OR (95% CI) 
PFHxS no  1.27 (0.16; 10.15) 0.66  0.63 (0.41; 0.97)  0.88 (0.64; 1.21)  0.91 (0.58; 1.43) yes  0.80 (0.53; 1.20)   
PFOS  no  8.94 (0.27; 299.11) 0.18  0.69 (0.43; 1.09)  0.90 (0.63; 1.29)  0.66 (0.39; 1.11) yes  0.82 (0.53; 1.28)   
PFOA  no  4.48 (0.42; 47.69) 0.17  0.93 (0.57; 1.53)  1.03 (0.70; 1.51)  0.69 (0.40; 1.20) yes  0.82 (0.49; 1.36)   
PFNA  no  371.98 (0.16; 8.62*10
5) 0.12  0.81 (0.52; 1.28)  0.82 (0.57; 1.16)  0.55 (0.32; 0.94) yes  0.77 (0.49; 1.22)   
PFDA  no  401.88 (0.09; 1.84*10
6) 0.15  0.84 (0.55; 1.29)  0.81 (0.59; 1.13)  0.68 (0.42; 1.12) yes  0.88 (0.58; 1.34)   
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, allergic 
eczema and hay fever, maternal pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of breastfeeding, and fish intake 
at age 13.  
a Additionally adjusted for birth weight, and family history of chronic bronchitis/asthma. 
i p-value for PFAS/MMR vaccination interaction. 
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Table 5: OR for history of allergic and non-allergic asthma associated with a doubling of serum PFAS concentrations at age 5 
  Age 5  Age 13 
Age 5 
PFASs 
MMR 
vaccination 
before age 5 
 Atopic asthma a  
N=494 
 Non-atopic asthma b  
N=511 
 Atopic asthma c  
N=456 
 Non-atopic asthma d  
N=443     
 OR (95% CI) p i  OR (95% CI) p i  OR (95% CI) p i  OR (95% CI) p i 
PFHxS no  9.30 (1.20; 72.09) 0.02  1.66 (0.32; 8.71) 0.36  1.86 (0.52; 6.69) 0.29  3.31 (0.36; 30.74) 0.26 yes  0.80 (0.47; 1.38)  0.75 (0.48; 1.17)  0.91 (0.58; 1.42) 0.90 (0.52; 1.55) 
PFOS no  53.10 (1.50; 1881.81) 0.04  0.08 (0.00; 27.08) 0.47  2.64 (0.24; 29.32) 0.27  8.19 (0.04; 1743.69) 0.55 yes  1.16 (0.44; 3.03)  0.73 (0.34; 1.58)  0.65 (0.29; 1.49) 1.56 (0.65; 3.77) 
PFOA no  46.98 (1.26; 1747.34) 0.02  1.20 (0.06; 64.44) 0.62  6.40 (0.80; 50.97) 0.03  20.94 (0.34; 1295.34) 0.12 yes  0.57 (0.19; 1.66)  0.79 (0.37; 1.72)  0.57 (0.25; 1.31) 0.75 (0.29; 1.95) 
PFNA no  75.81 (1.24; 4636.88) 0.02  4.24 (0.28; 63.54) 0.17  6.99 (1.06; 45.86) 0.02  14.16 (0.05; 3837.15) 0.34 yes  0.61 (0.25; 1.52)  0.62 (0.32; 1.18)  0.59 (0.30; 1.15) 0.92 (0.45; 1.88) 
PFDA no  18.42 (2.02; 168.04) <0.01  1.72 (0.30; 9.66) 0.37  2.43 (0.69; 8.56) 0.05  1.82 (0.16; 20.17) 0.53 yes  0.52 (0.25; 1.05)  0.75 (0.45; 1.23)  0.63 (0.36; 1.10) 0.83 (0.48; 1.44) 
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, allergic eczema and hay fever, maternal 
pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of breastfeeding, fish intake at age 5, number of siblings, daycare attendance at age 5, birth 
weight, and family history of chronic bronchitis/asthma. 
a Both asthma and allergy at age 5. 
b Asthma but not allergy at age 5. 
c Both asthma and positive skin prick test at age 13. 
d Asthma but no positive skin prick test at age 13. 
i p-value for PFAS/MMR vaccination interaction. 
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Appendix A: Imputation models 
 
Model a Use of data from the model Variables included in the imputation model Interactions 
1 All analyses except associations between PFASs 
and allergy (questionnaire) at age 13 and atopic 
eczema at age 13  
Binary b: 
MMR vaccination, parental smoking in the home at ages 5 and 13, use of 
daycare at age 5, has furry pets at age 13, father’s primary education, whether 
the child had lived abroad between ages 7 and 13, asthma at age 5, allergy at 
age 5, asthma at age 13, positive SPT at age 13, rhinoconjunctivitis at age 13 
Ordered categorical c: 
Number of siblings, weekly maternal fish dinners, weekly fish dinners at ages 
5 and 13 
Non-ordered categorical d: 
Family history of chronic bronchitis or asthma, family history of eczema in 
children, allergic eczema and hay fever, family history of allergy 
Continuous with truncation e: 
Total months of breastfeeding 
Continuous f: 
Maternal PFHxS, PFOS, PFOA, PFNA and PFDA, child PFHxS, PFOS, 
PFOA, PFNA and PFDA at age 5, child PFHxS, PFOS, PFOA, PFNA and 
PFDA at age 13, umbilical cord IgE, IgE at age 7 
Complete (no missing):  
Sex, premature birth, birth season, birth weight, maternal pre-pregnancy BMI, 
maternal smoking during pregnancy, maternal parity 
 
Interactions between MMR 
vaccination and each of the variables 
PFHxS, PFOS, PFOA, PFNA and 
PFDA at age 5 were included in the 
imputation of asthma at age 5, 
allergy at age 5, asthma at age 13 
 
 
2 Analyses of association between:  
- all PFASs and allergy (questionnaire) at age 13 
- maternal PFASs + PFASs at age 5 and eczema 
at age 13 
- PFOS, PFOA, PFNA, and PFDA at age 13 and 
eczema at age 13 
 
All variables from model 1 except asthma at age 13, positive SPT at age 13, 
and rhinoconjunctivitis at age 13 
 
Binary b: 
Allergy (questionnaire) at age 13 and atopic eczema at age 13 
Interactions between MMR 
vaccination and each of the variables 
PFOS, PFOA, PFNA, and PFDA at 
age 13 were included in the 
imputation of eczema (age 13) 
3 Analyses of association between PFHxS at age 13 
and eczema at age 13 
All variables from model 1 except asthma at age 13 and positive SPT at age 13 
 
Binary b: 
Atopic eczema at age 13 
 
An interaction between MMR 
vaccination and PFHxS at age 13 
were included in the imputation of 
eczema (age 13) 
a We were unable to create an imputation model including all allergy measures at age 13, and data was therefore imputed in three different models 
b Binary variables were imputed using logistic regression 
c Ordered categorical variables were imputed using ordered logistic regression 
d Non-ordered categorical variables were imputed using multinomial logistic regression 
e Duration of breastfeeding was imputed using linear regression left truncated at zero 
f Other continuous variables were imputed using classic linear regression 
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Appendix B: Associations between parental/child characteristics and PFAS tested in linear regression models, N = 559 
 
   Maternal PFAS  
5 years PFAS 
 
13 years PFAS 
 
% difference a % difference a % difference a 
  PFHxS PFOS PFOA PFNA PFDA  PFHxS PFOS PFOA PFNA PFDA  PFHxS PFOS PFOA PFNA PFDA 
Sex Girls  - - - - -  5.8 1.9 -4.9 -5.4 -3.7  -16.2 -16.4  -10.6 -14.2 -14.6 
 p  - - - - -  0.29 0.51 0.08 0.13 0.38  <0.01 <0.01 <0.01 <0.01 <0.01 
Premature birth 
(<=36 weeks) 
Yes  - - - - -  -10.6 -1.9 -7.3 1.0 34.3  3.1 12.9 -3.3 14.4 28.9 
p  - - - - -  0.56 0.86 0.47 0.94 0.05  0.82 0.32 0.77 0.28 0.06 
Birth season Summer  -27.4 -5.5 -8.1 -4.2 4.4  - - - - -  - - - - - 
 Fall  -22.8 1.6 -5.5 -5.7 0.2  - - - - -  - - - - - 
 Winter  -27.7 -2.5 -7.4 -7.2 0.7  - - - - -  - - - - - 
 p  0.01 0.16 0.24 0.51 0.83  - - - - -  - - - - - 
Birth weight (kg)   - - - - -  -5.5 -2.5 -2.6 -1.2 -4.0  -0.2 2.0 -3.1 -0.2 4.2 
p  - - - - -  0.28 0.38 0.36 0.73 0.32  0.95 0.57 0.31 0.95 0.28 
Total months of 
breastfeeding 
  -0.6 -0.6 -0.9 -0.8 -0.5  2.8 1.7 1.6 1.2 0.8  0.6 0.5 0.6 0.2 -0.1 
p  0.3 b <0.01
 
b 
<0.01 
b 
<0.01 
b 0.09
 b  <0.01 b <0.01
 
b 
<0.01 
b 
<0.01 
b 0.01
 b  0.03 b 0.05 b 0.02 b 0.47 b 0.65 b 
Maternal parity 
(pre-pregnancy) 
1  -15.7 -1.9 -22.2 -2.8 5.0  1.0 0.2 2.1 3.7 4.6  6.6 3.8 3.2 2.4 3.8 
>=2  -17.5 0.5 -25.2 9.3 15.7  -2.8 -0.5 0.1 8.3 1.7  5.6 -0.4 1.8 1.3 3.3 
p  0.08 0.70 <0.01 0.01 0.01  0.81 0.98 0.81 0.21 0.73  0.40 0.56 0.77 0.87 0.73 
Number of siblings 
(at age 5) 
1  - - - - -  29.4 17.9 12.6 8.1 -1.2  2.4 0.4 -2.6 -5.1 -1.0 
2  - - - - -  31.7 17.4 12.8 12.2 -3.9  9.3 1.8 -1.1 -1.2 1.8 
>=3  - - - - -  8.3 11.7 6.5 10.2 -4.7  -4.3 -4.0 -6.7 -6.2 -0.9 
p  - - - - -  0.01 0.03 0.12 0.45 0.89  0.08 0.69 0.62 0.62 0.93 
Received 15-month 
MMR-vaccination 
Yes  - - - - -  -0.6 8.4 -8.3 4.7 16.5  4.7 7.4 -6.7 11.4 14.7 
p  - - - - -  0.96 0.28 0.25 0.63 0.16  0.65 0.44 0.41 0.24 0.18 
Maternal pre-
pregnancy BMI 
(kg/m2) 
  -0.7 0.34 0.1 0.5 0.1  -2.8 -1.1 -1.1 -0.3 -0.6  -1.5 -1.0 -0.9 -0.5 -0.5 
p  0.42 0.26 0.77 0.25 0.89  <0.01 b <0.01
 
b 
<0.01 
b 0.52
 b 0.24 b  <0.01 b 0.02 b 0.02 b 0.26 b 0.26 b 
Maternal smoking 
during pregnancy 
Yes  -11.0 -3.9 2.9 -7.8 -6.7  -18.2 -11.3 -3.4 -10.7 -8.5  -11.8 -11.3 -1.5 -7.5 -10.5 
p  0.13 2 0.14 2 0.40 2 0.04 2 0.10 2  <0.01 b <0.01
 
b 0.28
 b <0.01
 
b 0.06
 b  <0.01 b <0.01
 
b 0.68
 b 0.05 b 0.01 b 
Parental smoking in 
the home at age 5 
Yes  - - - - -  -13.3 -6.3 -2.4 -6.2 -9.8  -9.1 -10.1 -1.2 -6.7 -4.3 
p  - - - - -  0.02 b 0.05 b 0.46 b 0.12 b 0.03 b  0.03 b 0.01 b 0.74 b 0.08 b 0.32 b 
Parental smoking in 
the home at age 13 
Yes  - - - - -  - - - - -  -1.8 -6.9 1.7 -2.7 -4.6 
p  - - - - -  - - - - -  0.77 0.22 0.75 0.65 0.48 
Weekly maternal 
fish dinners during 
pregnancy 
2   -6.8 5.6 -3.5 5.6 4.6  -15.3 -0.4 -0.6 6.4 6.7  -4.9 2.8 -0.4 6.4 9.1 
>2  -2.2 11.3 -4.7 12.3 12.3  -23.2 2.5 -5.9 11.5 14.9  -4.7 8.8 -4.0 12.2 20.8 
p  0.89 b 0.03 b 0.61 b 0.10 b 0.14 b  <0.01 b 0.82 b 0.29 b 0.14 b 0.16 b  0.60 b 0.25 b 0.69 b 0.09 b 0.01 b 
Weekly fish dinners 
at age 5  
 
>1 – 2  - - - - -  -12.7 3.7 -1.2 7.0 23.7  -6.0 9.7 -1.0 12.1 14.0 
>2  - - - - -  -22.6 5.2 -5.9 17.7 31.1  -7.2 13.9 -4.0 17.8 26.6 
p  - - - - -  <0.01 b 0.48 b 0.20 b <0.01 <0.01  0.39 b 0.03 b 0.57 b 0.01 b <0.01 b 
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b b 
Weekly fish dinners 
at age 13  
>1 – 2  - - - - -  - - - - -  -0.9 6.7 0.6 12.7 12.2 
>2  - - - - -  - - - - -  10.3 20.2 -1.2 26.7 33.0 
p  - - - - -  - - - - -  0.17 b <0.01
 
b 0.93
 b <0.01
 
b <0.01
 b 
Use of daycare at 
age 5 
Yes  - - - - -  10.8 -3.4 7.9 11.1 16.2  5.3 -3.2 10.4 -3.8 -13.4 
p  - - - - -  0.31 0.53 0.17 0.13 0.06  0.48 0.63 0.11 0.56 0.05 
Has furry pets at 
age 13 
Yes  - - - - -  - - - - -  4.6 -0.0 0.2 -1.8 -1.4 
p  - - - - -  - - - - -  0.26 0.99 0.95 0.62 0.72 
Family history 
of chronic 
bronchitis or 
asthma 
From one 
parent  -0.4 0.9 1.9 -1.7 4.1  -8.6 -5.2 -1.5 -1.0 -2.2  -5.9 -5.6 1.8 -1.7 -3.1 
From both 
parents  17.8 8.1 20.2 0.6 5.2  -12.6 1.4 -0.3 -5.0 12.7  -15.5 -0.7 3.5 1.2 1.6 
p  0.59 0.42 0.03 0.91 0.65  0.25 0.27 0.91 0.82 0.35  0.10 0.36 0.82 0.89 0.76 
Family history 
of eczema in 
children, 
allergic eczema 
and hay fever 
From one 
parent  -14.1 -7.3 -7.8 -8.1 -7.7  -4.2 -6.7 0.5 0.8 -0.1  -4.6 -5.9 -1.0 -1.7 -8.1 
From both 
parents  -14.1 -0.3 -4.5 4.1 12.0  -7.2 -6.2 3.2 1.7 1.6  -10.5 -9.1 -5.1 -7.8 -6.3 
p  0.18 b 0.02 b 0.08 b 0.05 b 0.01 b  0.65 0.10 0.82 0.96 0.97  0.19 b 0.16 b 0.64 b 0.40 b 0.18 b 
Family history 
of allergy 
From one 
parent  -23.8 -1.3 -2.1 -5.9 -4.3  -3.1 -3.5 0.1 -2.5 -7.6  -9.6 -7.8 -0.0 -4.7 -9.4 
From both 
parents  -24.1 2.0 -0.3 0.4 -1.0  -8.9 -6.4 0.8 0.9 2.7  -3.9 2.1 1.0 0.8 4.0 
p  <0.01 0.79 0.86 0.35 0.67  0.67 0.46 0.99 0.83 0.25  0.10 b 0.10 b 0.99 b 0.47 b 0.05 b 
Factors were considered associated with PFAS if they were associated (p<0.20) with at least two PFAS measures in the same direction at a particular time point. 
a The estimates of association were converted to express percent differences in PFAS. 
b In adjusted models including both breast feeding, pre-pregnancy BMI, maternal smoking during pregnancy, parental smoking at age 5, fish intake, family disposition for eczema/hay fever, 
and family disposition for allergy, parental smoking at age 5 was no longer associated with PFAS concentrations, maternal fish intake during pregnancy was no longer associated with PFAS 
at ages 5 and 13, and fish intake at age 5 was no longer associated with PFAS concentrations at age 13. Also, family disposition for eczema/hay fever and family disposition for allergy were 
no longer associated with PFAS concentrations at age 13, but when family disposition for allergy was removed from the adjusted model, family disposition for eczema/hay fever was still 
associated with PFAS at age 13. 
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Appendix C: Distributions of PFASs by MMR vaccination status at age 5 and asthma status at ages 5 and 13 years (pre-imputation) 
 
  
  MMR vaccinated  MMR unvaccinated 
  
  
Age 5 asthma 
Median (min; max) 
No asthma at age 5 
Median (min; max)  
Age 5 asthma 
Median (min; max) 
No asthma at age 5 
Median (min; max) 
Maternal PFASs (ng/mL)  N=69 N=426  N=8 N=13 
 PFHxS  4.2 (1.0; 26.5) 4.6 (0.6; 25.7)  3.0 (1.3; 9.0) 6.2 (1.3; 11.7) 
 PFOS   28.4 (10.6; 66.7) 27.4 (9.4; 68.8)  28.3 (15.9; 34.0) 24.0 (15.4; 36.4) 
 PFOA   3.6 (1.3; 6.2) 3.2 (0.8; 8.4)  2.8 (1.3; 4.0) 3.5 (2.1; 4.6) 
 PFNA   0.6 (0.2; 1.9) 0.6 (0.2; 2.5)  0.7 (0.3; 1.1) 0.6 (0.3; 0.8) 
 PFDA   0.3 (0.1; 0.8) 0.3 (0.0; 1.2)  0.3 (0.1; 0.7) 0.3 (0.2; 0.5) 
Age 5 PFASs (ng/mL)  N=66 N=427  N=6 N=14 
 PFHxS   0.6 (0.0; 3.0) 0.6 (0.1; 19.5)  1.0 (0.3; 1.3) 0.5 (0.2; 1.6) 
 PFOS   16.2 (3.3; 33.3) 17.1 (6.2; 48.2)  18.7 (9.2; 27.2) 14.1 (8.8; 27.8) 
 PFOA   4.0 (0.8; 7.9) 4.0 (1.5; 15.4)  5.0 (3.6; 11.4) 3.5 (2.7; 7.3) 
 PFNA   0.9 (0.5; 3.2) 1.0 (0.4; 6.2)  1.3 (0.6; 3.9) 0.8 (0.5; 1.6) 
 PFDA   0.3 (0.1; 0.8) 0.3 (0.1; 1.2)  0.4 (0.1; 0.7) 0.2 (0.1; 0.8) 
 
  
Age 13 asthma 
Median (min; max) 
No asthma at age 13 
Median (min; max)  
Age 13 asthma 
Median (min; max) 
No asthma at age 13 
Median (min; max) 
Maternal PFASs (ng/mL)  N=73 N=372  N=9 N=9 
 PFHxS   4.3 (0.7; 26.5) 4.6 (0.6; 25.7)  3.0 (1.3; 9.0) 8.3 (1.3; 11.7) 
 PFOS   28.0 (15.8; 66.7) 27.5 (9.4; 57.0)  30.6 (15.9; 36.4) 21.4 (15.4; 33.0) 
 PFOA   3.5 (1.1; 6.5) 3.2 (0.8; 8.4)  3.8 (1.3; 4.1) 2.8 (2.1; 4.0) 
 PFNA   0.6 (0.3; 1.9) 0.6 (0.2; 1.8)  0.8 (0.3; 1.1) 0.6 (0.3; 0.6) 
 PFDA  0.3 (0.1; 0.8) 0.3 (0.0; 0.7)  0.3 (0.1; 0.7) 0.3 (0.2; 0.3) 
Age 5 PFASs (ng/mL)  N=70 N=376  N=7 N=10 
 PFHxS   0.6 (0.0; 1.6) 0.6 (0.1; 19.5)  0.6 (0.3; 1.3) 0.5 (0.2; 1.6) 
 PFOS   16.5 (3.3; 31.3) 17.1 (6.2; 40.8)  18.6 (9.2; 27.8) 13.1 (10.4; 23.3) 
 PFOA   4.0 (0.8; 7.9) 4.0 (1.3; 15.4)  5.0 (3.6; 11.4) 3.1 (2.7; 7.3) 
 PFNA   0.9 (0.5; 3.1) 1.0 (0.4; 5.3)  1.2 (0.5; 3.9) 0.8 (0.5; 1.6) 
 PFDA  0.3 (0.1; 1.0) 0.3 (0.1; 1.2)  0.3 (0.1; 0.7) 0.2 (0.1; 0.8) 
Age 13 PFASs (ng/mL)  N=73 N=392  N=8 N=10 
 PFHxS   0.4 (0.1; 1.2) 0.4 (0.1; 4.1)  0.4 (0.2; 0.7) 0.3 (0.2; 0.6) 
 PFOS   6.8 (1.5; 14.0) 6.7 (1.0; 16.6)  6.7 (3.9; 9.1) 6.4 (3.5; 8.4) 
 PFOA   2.0 (0.7; 4.0) 2.0 (0.6; 6.1)  2.1 (1.2; 3.5) 2.0 (1.1; 3.0) 
 PFNA   0.7 (0.2; 1.7) 0.7 (0.2; 2.1)  0.7 (0.3; 1.2) 0.7 (0.4; 0.9) 
 PFDA  0.3 (0.1; 0.8) 0.3 (0.1; 1.2)  0.2 (0.2; 0.7) 0.3 (0.1; 0.5) 
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